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A randomized trial comparing clopidogrel versus
ticlopidine therapy in patients undergoing infarct
artery stenting for acute myocardial infarction with
abciximab as adjunctive therapy
Guido Parodi, MD, PhD, FESC,a Roberto Sciagra`, MD,b Angela Migliorini, MD,a Gentian Memisha, MD,a
Guia Moschi, MD,a Renato Valenti, MD,a Alberto Pupi, MD,b and David Antoniucci, MDa Florence, ItalyAim To evaluate the impact of a clopidogrel therapy on the effectiveness of myocardial reperfusion in patients with
ST-segment elevation acute myocardial infarction (AMI) undergoing routine infarct-related artery (IRA) stent implantation and
receiving routine abciximab therapy.
Background Inflammatory processes after mechanical restoration of flow in AMI play a central role in decreasing the
effectiveness of reperfusion at microcirculatory level. Several studies suggest that clopidogrel may exert a protective effect
against adverse cardiovascular events by virtue of its anti-inflammatory properties.
Methods A total of 133 patients with a first ST-elevation AMI were randomized to clopidogrel (600-mg loading dose
before IRA stenting followed by 75 mg daily, n = 66) or ticlopidine (500 mg before IRA stenting followed by 250 mg
twice daily, n = 67). The primary end point was scintigraphic infarct size at 1 month. The secondary end points were ST-
segment elevation resolution within 3 hours of procedure and 1-month clinical outcome, as a composite of death, reinfarction,
target vessel revascularization, and stroke within 1 month of the index procedure.
Results The 1-month technetium 99m sestamibi scintigraphy revealed similar infarct size (16.2% F 14.6% vs 15.0%
F 14.1%, P = .703) and severity (0.48 F 0.18 vs 0.49 F 0.15, P = .592) in the clopidogrel group as compared with the
ticlopidine group. Three-hour ST-segment resolution rate was similar in the 2 study groups (86% vs 89%, P = .642).
At 1 month, there was no difference in major cardiovascular adverse event rate (3% vs 3%, P = .988). Discontinuation of
thienopiridine therapy within the first month occurred in no patient randomized to clopidogrel and in 3 (4.5%) patients
randomized to ticlopidine ( P = .082).
Conclusion Clopidogrel has no impact on the effectiveness of myocardial reperfusion in patients with AMI treated
routinely with stenting and abciximab. However, clopidogrel, administered as a 600-mg loading dose followed by 75 mg
daily, is safe and at least as effective as the standard ticlopidine therapy in this subgroup of patients. (Am Heart J
2005;150:220.e1 -220.e5.)Inflammatory processes after mechanical restoration
of flow in acute myocardial infarction (AMI) play a
central role in decreasing the effectiveness of reperfu-
sion at microcirculatory level. Some effective pharma-
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doi:10.1016/j.ahj.2005.04.010that is related to their anti-inflammatory properties that
are distinct from their perceived primary mechanism of
action. This is the case of abciximab that provides an
early protective effect against stented vessel failure due
to the inhibition of IIb/IIIa platelet receptor and a
relevant effect at microcirculatory level with the inhibi-
tion of the inflammatory cascade started by athero-
thrombotic and platelet aggregates at microcirculatory
level and subsequent leukocytes activation, resulting in
increased myocardial salvage and smaller infarcts.1,2
Several studies suggest that the antiplatelet agent
clopidogrel may exert a protective effect against
adverse cardiovascular events by virtue of its anti-
inflammatory properties as well. Recently, it has been
shown that clopidogrel may reduce platelet-leukocyte
aggregates and P-selectin expression.3,4 Formation of
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is one of the mechanisms by which leukocytes
contribute to inflammation, and clopidogrel may inhibit
the expression of CD62 ligand.4 Thus, there is the
potential for a synergistic anti-inflammatory effect of
clopidogrel as adjunctive treatment to abciximab.5
To evaluate the impact of clopidogrel therapy (600-mg
loading dose followed by 75 mg daily) on effectiveness of
myocardial reperfusion in patients with ST-segment
elevation AMI undergoing routine infarct-related artery
( IRA) stent implantation and receiving routine abciximab
therapy, we performed an unblinded randomized trial
comparing clopidogrel with standard ticlopidine therapy.
We chose to treat control arm patients with ticlopi-
dine (250 mg twice daily) because it has became the
reference antithrombotic therapy after coronary stent-
ing, although full effect requires a few days because of
the delayed onset of action.6 On the contrary, clopi-
dogrel (an antiplatelet agent closely related to ticlopi-
dine in chemical structure and action) does not cause
the adverse events that limit ticlopidine therapy and has
a faster onset of action, especially when early activity is
achieved by a clopidogrel loading dose.7
Methods
Study population
Criteria for enrolment included (1) chest pain persisting N30
minutes associated with ST-segment elevation of at least 0.1 mV
in z2 contiguous electrocardiographic leads and (2) admission
within 12 hours of symptom onset. Patients with cardiogenic
shock due to predominant ventricular failure were included.
Cardiogenic shock due to predominant ventricular failure was
defined as systolic blood pressure b90 mm Hg (without
inotropic or intra-aortic balloon support) that is thought to be
secondary to ventricular dysfunction and associated with signs
of end-organ hypoperfusion such as cold or diaphoretic
extremities or altered mental status or anuria. The exclusion
criteria included ongoing thienopiridine therapy, previous
myocardial infarction, previous administration of fibrinolytic
therapy, participation in another study, inability to obtain
informed consent, and a reference IRA diameter b2.5 mm.
Evidences of massive coronary thrombus, diffuse disease, a
major branch involved in the culprit lesion, or severe vessel
tortuosity were not considered contraindications to IRA
stenting. The use of thrombectomy and direct stenting was at
discretion of the operator.
Before catheterization, patients received 250 mg of aspirin
intravenously.
After coronary angiography, patients were randomly
assigned to clopidogrel (600 mg) or ticlopidine (500 mg).
Randomization was carried out by computer-generated
sequence, and assignment was performed using a closed
envelope system. Thienopiridine loading dose was adminis-
tered immediately before the intervention.
All randomized patients received abciximab if not contra-
indicated (ReoPro, Centocor, Malvern, Pa) immediately before
the procedure as a bolus of 0.25 mg/kg of body weight
followed by a 12-hour infusion at a rate of 0.125 Ag/kg perminute. Heparin was given as an initial bolus of 70 U/kg, and
additional boluses were administered during the procedure to
achieve an activated clotting time of 200 to 300 seconds.
Patients were thereafter treated with aspirin (325 mg/d
indefinitely), and ticlopidine (250 mg twice daily for 6 months)
or clopidogrel (75 mg daily for 6 months), as previously
assigned. The use of atorvastatin was strongly encouraged at
discharge. The study protocol was approved by the institu-
tional Ethical Committee and patient’s informed consent
was obtained.
End points and outcome measures
The primary end point of the study was infarct size as
assessed by technetium 99m (99mTc) sestamibi scintigraphy at
1 month. The secondary end points were (1) the effectiveness
of myocardial reperfusion as assessed by ST-segment elevation
resolution analysis within 3 hours of procedure and (2)
1-month clinical outcome, as a composite of death from any
cause, reinfarction, target vessel revascularization, and stroke
within 1 month of the index procedure (patients with N1
event were assigned the highest-ranked event according to the
previous list).
The 1-month 99mTc sestamibi scintigraphic determinations
of infarct size and severity at 1 month were performed as
previously described.8
A 12-lead electrocardiogram was recorded before procedure
and 3 hours after IRA recanalization. The ST-segment changes
were evaluated in the single lead with the most prominent
ST-segment elevation before mechanical intervention. The
ST-segment elevation was measured to the nearest 0.5 mm at
60 milliseconds after the J point with the aid of handheld
calipers. According to a previous report,9 early ST-segment
elevation resolution was defined as z50% decrease in
ST-segment elevation after IRA recanalization. Investigators
who were unaware of patient treatment assignment and
clinical outcome performed independent analyses of the
electrocardiograms, scintigraphies, and angiographies.
Creatine kinase (CK), white blood cell, and platelet count
measurements were systematically performed on admission
and every 3 hours for the subsequent 24 hours and then every
12 hours for 2 days. The peak value of CK and the time-to-peak
CK was estimated for each patient. Blood samples for
C-reactive protein and creatinine measurements were drawn
on patient’s admission.
Reinfarction was defined as recurrent chest pain with
ST-segment or T-wave changes and recurrent elevation of
cardiac enzymes. Repeat target vessel revascularization was
defined as coronary angioplasty or coronary surgery performed
because of restenosis or reocclusion of the IRA. Stroke was
defined as an acute neurologic defect that lasts N24 hours and
results in death or inability to perform normal activities.
Statistical analysis
The sample size was calculated on the assumption that
clopidogrel therapy reduces 1-month scintigraphic infarct size
by 30%. To detect a difference with 80% power and a type I
error (a) of .05, 200 patients per group were required. Interim
analyses were planned after one third (N = 133) of study patient
enrollment. Discrete data are summarized as frequencies,
whereas continuous as mean F SD. m2 Test analysis was used
for comparison of categorical variables. Student t test was used
Table I. Baseline characteristics
Clopidogrel
(n = 66)
Ticlopidine
(n = 67) P
Age (y) 66 F 12 69 F 13 .154
Male 47 (71) 45 (67) .613
Current smoker 18 (27) 26 (39) .158
Hypertension 31 (47) 31 (47) .935
Cholesterolemia N200 mg/dL 27 (41) 18 (27) .087
Diabetes mellitus 8 (12) 14 (21) .173
Anterior infarct location 35 (53) 29 (43) .261
Cardiogenic shock 5 (8) 5 (8) .980
Infarct artery .471
Left anterior
descending artery
35 (53) 29 (43)
Right coronary artery 24 (36) 31 (46)
Circumflex coronary artery 7 (11) 6 (9)
Venous graft 0 (0) 1 (2)
Multivessel disease 37 (56) 34 (51) .539
Preprocedural TIMI
grade flow 0-1
53 (80) 52 (78) .703
Time of ischemia (h) 3.5 F 2.0 3.1 F 1.8 .225
C-reactive protein (mg/L) 3.32 F 4.43 2.44 F 3.00 .286
White blood cell
count (109/L)
10.9 F 3.8 11.4 F 3.6 .434
Creatinine (mg/dL) 1.18 F 0.99 1.11 F 0.39 .579
Values are presented as number (%) or mean F SD.
Table II. Procedural data
Clopidogrel
(n = 66)
Ticlopidine
(n = 67) P
Intra-aortic balloon
counterpulsation
6 (9) 4 (6) .495
Abciximab administration 63 (96) 66 (99) .303
Rheolytic thrombectomy 25 (38) 27 (40) .775
Infarct artery stenting 66 (100) 67 (100) 1.000
Direct stent implantation 38 (58) 40 (60) .803
Multiple stents implantation 12 (24) 13 (26) .817
Procedural success 64 (97) 66 (98) .221
Peak CK value (U/L) 2886 F 2768 2585 F 2381 .503
Time-to-peak CK (h) 6.6 F 4.6 6.5 F 3.9 .942
Bleeding complications 2 (3) 1 (2) .550
Neutropenia (b1.5  109/L) 0 (0) 0 (0) 1.000
Thrombocytopenia
(b100  109/L)
1 (2) 1 (2) .990
ACE inhibitors recommended
at discharge
57 (86) 56 (86) .972
h-Blockers recommended
at discharge
25 (38) 19 (29) .295
Statins recommended
at discharge
60 (92) 55 (82) .121
Values are presented as number (%) or mean F SD. ACE, Angiotensin-converting
enzyme.
Table III. One-month outcomes
Clopidogrel
(n = 66)
Ticlopidine
(n = 67) P
99mTc sestamibi infarct size (%) 16.2 F 14.6 15.0 F 14.1 .703
99mTc sestamibi infarct severity 0.48 F 0.18 0.49 F 0.15 .592
3-hour ST-segment
elevation resolution
50 (86) 49 (89) .642
Death 1 (1.5) 2 (3) .568
Reinfarction 1 (1.5) 0 (0) .312
Target vessel revascularization 0 (0) 0 (0) 1.000
Stroke 0 (0) 0 (0) 1.000
Composite 1-month
adverse events
2 (3) 2 (3) .988
Values are presented as number (%) or mean F SD.
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asymmetrical distribution of infarct size values, the Mann-
Whitney U test was used for the primary end point. All analyses
were conducted according to the intention-to-treat principle.
P b .05 was considered significant. Analyses were performed
with SPSS for Windows, version 11.5 (SPSS Inc, Chicago, Ill).
Results
Between December 2003 and August 2004, a total of
133 patients were randomized to clopidogrel (n = 66) or
ticlopidine (n = 67) therapy. The trial was stopped
prematurely (after the enrollment of one third of the
planned patients) because of no detectable trend toward
infarct size reduction by clopidogrel treatment.
The reasons for exclusion of 32 patients from
randomization were ongoing thienopiridine therapy
(9 patients), previous myocardial infarction (9), partici-
pation in another study (7), IRA diameter b2.5 mm (4),
and inability to obtain informed consent (3).
Table I summarizes the baseline patient characteristics
and Table II the procedural data. Patients randomized to
clopidogrel were younger and had a greater incidence of
dyslipidemia and a lower incidence of diabetes and
smoking, but all these differences did not reach
statistical significance. There were no differences in
procedural success between the 2 groups. All study
patients had IRA stenting. Nearly all patients of both
groups received abciximab treatment.Bleeding complications requiring blood transfusion,
neutropenia (b1.5  109/L), and thrombocytopenia
(b100  109/L) occurred in 3%, 0%, and 1% of the
patients randomized to clopidogrel and in 2%, 0%, and
2% of the patients randomized to ticlopidine, respec-
tively ( P = NS).
Discontinuation of thienopiridine therapy within the
first month occurred in no patient randomized to
clopidogrel and in 3 (4.5%) patients randomized to
ticlopidine ( P = .082). The causes for discontinuation
were gastrointestinal disorder (n = 2) and bleeding (n = 1).
The end point rates and outcomes are summarized in
Table III. The 1-month 99mTc sestamibi scintigraphy
revealed similar infarct size and severity in the clopidogrel
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hour ST-segment resolution rate was similar in the 2 study
groups. At 1 month, there were no differences in major
cardiovascular adverse event rates. The causes of death
were free wall rupture in 1 patient randomized to
clopidogrel and refractory heart failure in 2 patients
randomized to ticlopidine. Reinfarction occurred at day
4 in 1 patient randomized to clopidogrel due to subacute
stent thrombosis treated with thrombectomy and a new
angioplasty procedure.Discussion
Catheter-based reperfusion with adjunctive abciximab
therapy is considered nowadays as the preferred
reperfusion therapy for patients with AMI.10,11 In fact,
abciximab provides an early protective effect against
stented vessel failure due to the inhibition of IIb/IIIa
platelet receptor, and a relevant effect at microcircula-
tory level with the inhibition of the inflammatory
cascade. In clinical practice, clopidogrel, an antiplatelet
agent with anti-inflammatory properties, is frequently
administered in patients undergoing coronary stent
implantation. Thus, there is the potential for a syner-
gistic anti-inflammatory effect during the reperfusion
phase, of abciximab and clopidogrel, at least when early
activity is achieved by a clopidogrel loading dose.
The present study is the first randomized trial to
evaluate the clopidogrel additive anti-inflammatory
impact on myocardial reperfusion in patients with AMI
undergoing routine primary infarct artery stenting
with abciximab as adjunctive therapy.
This trial was stopped prematurely because of the
evidence of no clopidogrel treatment effect on the
primary end point (final infarct size) at the interim
analysis. We found no difference in final infarct size and
severity as well as ST-segment elevation resolution, a
reliable parameter of reperfusion at tissue level,12,13
between patients randomized to clopidogrel and those
randomized to ticlopidine. Likely, the well-known
benefit of clopidogrel treatment in patients with acute
coronary syndromes is not related to an increased
myocardial salvage and to smaller infarcts. However, the
results of this negative study allow some speculations.
Secondary end point data are consistent with the
hypothesis that 1-month adverse event rates, including
stent thrombosis and recurrent ischemic events, are
similar in patients treated with clopidogrel as compared
with those treated with ticlopidine. Clopidogrel (with a
loading dose) and ticlopidine therapy seems to provide
comparable efficacy in patients with AMI undergoing
routine infarct artery stenting, with abciximab as
adjunctive therapy. The dose of thienopiridine given at
the time of primary stenting appears to have no impact
on clinical outcomes in patients routinely treated
with abciximab.Clopidogrel treatment showed once again its good
tolerability. These results, achieved in patients with
ST-elevation AMI undergoing IRA primary stenting, are
consistent with previous randomized trials comparing
the outcome of clopidogrel and aspirin with ticlopidine
and aspirin in unselected patients undergoing intra-
coronary stent implantation.14-17
Study limitations
First, the present study was not powered to draw
definitive conclusions on clinical outcome and the
patient population was at relatively low risk (first AMI).
A large-scale, multicenter, randomized trial is needed to
evaluate the impact on clinical outcome of clopidogrel
treatment after IRA stenting. Second, a longer follow-up
period would be required to evaluate the actual long-
term benefit of clopidogrel treatment in patients with
ST-elevation AMI.18,19 Third, the medication use was not
blind. However, the end point measurements were
evaluated by investigators who were unaware of
patient’s treatment assignment.
Clinical implications
The results of the present trial underline that clopi-
dogrel, administered as a 600-mg loading dose followed
by 75 mg daily, is safe and at least as effective as the
standard ticlopidine therapy in patients with ST-eleva-
tion AMI treated routinely with stenting and abciximab.
In fact, even without an impact on the effectiveness of
myocardial reperfusion, this therapeutic regimen was
very well tolerated, had a zero side effect–related
discontinuation rate, and did not increase the risk of
bleeding.
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